van der Kolk, L E <br/><br/>
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.  [electronic resource] 

 -  Leukemia  Aug 2003 
 - 1658-64 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0887-6924 
<br/><br/><label>Standard No.: </label>10.1038/sj.leu.2402995  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Dose-Response Relationship, Drug<br/>Granulocyte Colony-Stimulating Factor--administration & dosage<br/>Humans<br/>Lactoferrin--blood<br/>Leukocyte Elastase--blood<br/>Lymphoma, B-Cell--drug therapy<br/>Middle Aged<br/>Neutrophil Activation--drug effects<br/>Recurrence<br/>Remission Induction<br/>Rituximab